Loading
NanoRepro AG Stock: price and insider trades · Germany
1 insider bought €15k of shares over the last 90 days, the latest filed 18 Aug 2026.
NanoRepro AG: what insiders have been doing
NanoRepro AG is a Healthcare & Pharma company based in Marburg, Germany. Its directors and officers file their transactions with BaFin. The last twelve months, up to 18 October 2026, brought 11 filings signed by 2 insiders.
Every open-market trade in the period is a purchase: 11 purchases worth €91k, from 2 insiders, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 board member and 1 senior executive among the declarants. Biggest ticket of the year: €18k, bought by Stiller, Dr. Olaf and made public on 29 May 2026 (0.072% of market cap).
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 18 August 2026, 60 days ago. Filings reach the BaFin feed a median of 2 days after the trade. The regulation allows three business days to notify a trade (MAR article 19).
For context, the typical company on the same exchange (median of 287 companies) published 5 filings over the same period, against 11 filings here. Over the whole record (from 2025), the tally stands at 14 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from BaFin disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Marburg, Germany
Source: Wikidata (CC0).
Insider Decl.
14
Thresholds
n/a
Buy Volume
€137,887
14 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDr. Olaf Stiller9 buys
Lisa Jüngst6 buys
Since the insiders bought
- -8.8%Entry €1.88 · Close 16 Oct 2026 €1.72
- -4.4%Entry €1.80 · Close 16 Oct 2026 €1.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate NanoRepro AG Strong Buy (bullish), based on 2 analysts. Average price target: €4.45.
Fundamental score
Ranked 14,316 of 24,148 companies
46.1
score / 100
Value57
Quality36
FCF yld42%
Earn yld-9.0%
EV/EBITDA·
ROE-5.3%
Gross mgn63%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
€1.80
Analyst consensus
2 analystsStrong buy
€4.40Target €4.45(+147%)€4.50
Income statement
Revenue€4.6M
Gross profit€2.9M63% margin
EBITDA-€3.4M-74% margin
Net income-€2.0M-45.8% margin
Valuation
PER (forward)-45.0x
P/Book0.6x
Beta0.44
Balance sheet & cash
Market cap€22.7M
Free Cash Flow€9.5M
Profitability & ownership
ROE-5.3%
ROA-3.4%
% insiders2.0%
% institutions9.1%
Last declaration on 18 August 2026
Declarations14 total
2,688.172 shares@ €1.860.024% mcap6.2% of flowShareXetraISIN DE0006577109BAFIN:40009328-f426a8007d4f
Canonical exit: 15 Nov 2026 (T+90)
5,261.579 shares@ €1.900.048% mcap12.4% of flowSharexetraISIN DE0006577109BAFIN:40009328-8c6eeea0c4af
Canonical exit: 29 Oct 2026 (T+90)
5,434.783 shares@ €1.840.041% mcap17.5% of flowShareXetraISIN DE0006577109BAFIN:40009328-25747d80e189
Canonical exit: 27 Aug 2026 (T+90)
30 shares@ €1.730.0002% mcap0.1% of flowShareXETRAISIN DE0006577109BAFIN:40009328-039c2b31aff5
Canonical exit: 26 Aug 2026 (T+90)
6,983.641 shares@ €1.840.053% mcap22.5% of flowShareXETRAISIN DE0006577109BAFIN:40009328-a8f95c647da8
Canonical exit: 27 Aug 2026 (T+90)
1,565.279 shares@ €1.790.011% mcap4.9% of flowShareXETRAISIN DE0006577109BAFIN:40009328-8cdab42a3773
Canonical exit: 25 Aug 2026 (T+90)
10,000 shares@ €1.750.072% mcap21.7% of flowShareXETRAISIN DE0006577109BAFIN:40009328-8847603b3e3a
Canonical exit: 26 Aug 2026 (T+90)
5,570.874 shares@ €1.750.040% mcap17.1% of flowShareTradegateISIN DE0006577109BAFIN:40009328-bfb6e96c25db
Canonical exit: 25 Aug 2026 (T+90)
5,965.031 shares@ €1.630.040% mcap12.0% of flowSharexetraISIN DE0006577109BAFIN:40009328-42fbba4a4565
Canonical exit: 24 Aug 2026 (T+90)
1,750.617 shares@ €1.620.012% mcap3.5% of flowShareXetraISIN DE0006577109BAFIN:40009328-d93c9ec726dd
Canonical exit: 20 Aug 2026 (T+90)
6,289.308 shares@ €1.590.041% mcap12.4% of flowShareTradegateISIN DE0006577109BAFIN:40009328-78add94750d0
Canonical exit: 17 Aug 2026 (T+90)
8,494.34 shares@ €1.6224.1% of flowShareTradegateISIN DE0006577109BAFIN:40009328-79567ed7ab47
Canonical exit: 29 Oct 2025 (T+90)
5,010.886 shares@ €1.5813.9% of flowShareTradegateISIN DE0006577109BAFIN:40009328-903602c6404d
Canonical exit: 2 Nov 2025 (T+90)
20,078.125 shares@ €1.2831.8% of flowShareXETRAISIN DE0006577109BAFIN:40009328
Canonical exit: 14 Aug 2025 (T+90)
14 of 14 declarations
About NanoRepro AG
NanoRepro AG is a German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) and headquartered in Marburg, Hesse, Germany. Since its stock market listing in October 2008, the group has focused on the development, manufacturing and distribution of rapid diagnostic self-tests for home and professional use, together with food supplements. Its core positioning is in preventive healthcare and self-diagnostics, a market supported by rising health awareness, consumer demand for convenient at-home testing, and multi-channel distribution across pharmacy, retail and online channels. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai))
From a business-model perspective, NanoRepro built its franchise around the “ZuhauseTEST” brand and a CE-marked portfolio covering areas such as fertility, pregnancy, gastric health, intolerances, allergies, preventive screening and infectious diseases. The company emphasizes product flexibility, just-in-time manufacturing and ongoing cost optimization, which are important advantages for a niche diagnostics player operating in a fast-moving consumer-health environment. Alongside diagnostics, NanoRepro has offered food supplements under the ALPHABIOL brand since 2015, allowing it to cross-sell within adjacent health and wellness categories. ([nanorepro.com](https://www.nanorepro.com/unternehmen?utm_source=openai))
Read moreShow less
In competitive terms, NanoRepro is best viewed as a focused small-cap specialist rather than a fully integrated large healthcare group. Its edge lies in speed, targeted product launches, and the combination of diagnostics with consumer health products. The company serves both domestic and international markets, although Germany remains the anchor market and operational base. Recent disclosures also indicate growing retail presence, including listings with major German drugstore partners, which supports broader brand visibility and distribution reach. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai))
Recent developments are especially relevant for investors. After the COVID-test windfall faded, NanoRepro reported a clear recovery in its underlying business in 2024, with core revenue outside COVID rising by roughly 76% and total revenue reaching about EUR 4.4 million. Subsequent half-year and full-year updates for 2024/2025 show continued momentum in self-tests and supplements, while profitability is still in transition. At the same time, the company has broadened its strategic optionality through a majority stake in Paedi Protect AG and a 2025 investment in hyped about science GmbH, linked to cold-plasma technology and the PHLAS consumer device. For international equity investors, NanoRepro combines healthcare exposure, balance-sheet-driven caution, and a diversification strategy that is still being built out. ([nanorepro.com](https://www.nanorepro.com/presse-news/pressemitteilungen-de/nanorepro-veroeffentlicht-halbjahreszahlen-2024-umsatz-im-kerngeschaeft-steigt-investitionen-in-markenbekanntheit-zahlen-sich-aus?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
